chartexchange

BioCardia Inc Reports Q3 2026 Loss Per Share of -$0. ...

GuruFocus | Nov 12, 2026 4:40 PM EST

Clinical-Stage Biotech Focuses on CardiAMP Approval Path and Helix Delivery System Related Stocks: BCDA ,

Read original article